HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lam, Q. Articles by Schneider, H.-G. Search for Related Content PubMed PubMed Citation Articles by Lam, Q. Articles by Schneider, H.-G. Related Collections Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors

Performance Evaluation and Subsequent Clinical Experience with the Abbott Automated Architect STAT Troponin-I Assay

¹ Clinical Biochemistry Unit, Alfred Pathology Service, The Alfred Hospital, and² Department of Medicine, Monash University, Melbourne, Australia;

^aaddress correspondence to this author at: Clinical Biochemistry Unit, Alfred Pathology Service, Commercial Road, Melbourne, Victoria 3004, Australia; fax 61-3-92763424, e-mail schneiderh{at}alfred.org.au)

Abstract

Background: Cardiac troponins are specific biochemical markers of myocardial injury used in the diagnosis of acute myocardial disease and cardiac risk stratification. To avoid misclassification of patients, troponin assays must demonstrate precision at the low end of the measuring range. We report our evaluation of the Architect STAT Troponin-I assay (Abbott Diagnostics), comparison of low-positive results with 2 other assays, and occurrence of heterophile antibody interference in the assay.

Methods: We assessed analytical performance on the ci8200 according to CLSI protocols, using quality-control and patient samples. Our healthy reference population included 480 blood donors. For correlation studies against the AxSYM first-generation cTnI (Abbott Diagnostics) and Access second-generation AccuTnI (Beckman Coulter) assays, we used 339 samples from hospital patients.

Results: The CV of the Architect STAT Troponin-I assay was 10% near the 99th percentile for the reference population (0.03 µg/L). Comparison with the AxSYM first-generation cTnI assay showed good correlation at higher concentrations, but better sensitivity of the Architect cTnI assay at low concentrations, which were clinically relevant as shown by review of patient histories. Correlation was good at the low end of the measuring range with the Access second-generation AccuTnI. Over the last 12 months we have identified 6 patients with heterophile antibodies causing positive interference.

Conclusions: The Architect STAT Troponin-I assay provides highly sensitive measurement of cTnI with a CV of 10% near the upper limit of a reference population; however, heterophile antibodies can interfere with this assay.

The following articles in journals at HighWire Press have cited this article:

				M. Bonham and S. Miller Clinical Comparison of 99th Percentile and 10% Coefficient of Variation Cutoff Values for Four Commercially Available Troponin I Assays Lab Med, August 1, 2009; 40(8): 470 - 473. [Abstract] [Full Text] [PDF]

				C. P. Chong, Q. T. Lam, J. E. Ryan, R. N. Sinnappu, and W. K. Lim Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients Age Ageing, March 1, 2009; 38(2): 168 - 174. [Abstract] [Full Text] [PDF]

				A. Mingels, L. Jacobs, E. Michielsen, J. Swaanenburg, W. Wodzig, and M. van Dieijen-Visser Reference Population and Marathon Runner Sera Assessed by Highly Sensitive Cardiac Troponin T and Commercial Cardiac Troponin T and I Assays Clin. Chem., January 1, 2009; 55(1): 101 - 108. [Abstract] [Full Text] [PDF]